Results 141 to 150 of about 8,512,443 (291)

Longitudinal changes in forced expiratory volume in 1 s in patients with eosinophilic chronic obstructive pulmonary disease. [PDF]

BMC Pulm Med, 2022
Jo YS, Moon JY, Park YB, Kim YH, Um SJ, Kim WJ, Yoon HK, Yoo KH, Jung KS, Rhee CK.   +9 more
europepmc   +1 more source

Decreased Forced Expiratory Volume [PDF]

, 2020
openaire   +1 more source

Ruta graveolens L. in Evidence‐Based Phytotherapy: Pharmacological Activities, Bioactive Compounds and Safety

Phytotherapy Research, EarlyView.
Graphical representation of ethnomedical uses, major bioactive compounds, pharmacological potential and toxicological risks of Ruta graveolens L. ABSTRACT Ruta graveolens L. is widely used in traditional European, Asian, African, and South American medicine for digestive, nervous, cardiovascular, respiratory, and reproductive disorders.
Tetiana Serhiienko, Victoriya Georgiyants, Liudas Ivanauskas, Olha Mykhailenko   +3 more
wiley   +1 more source

Machine Learning Prediction of Progression in Forced Expiratory Volume in 1 Second in the COPDGene® Study. [PDF]

Chronic Obstr Pulm Dis, 2022
Boueiz A, Xu Z, Chang Y, Masoomi A, Gregory A, Lutz SM, Qiao D, Crapo JD, Dy JG, Silverman EK, Castaldi PJ, COPDGene Investigators.   +11 more
europepmc   +1 more source

Forced Expiratory Volume as a Test for Successful Treatment of Asthma [PDF]

BMJ, 1958
W B, THOMSON, P, HUGH-JONES
openaire   +2 more sources

Pharmacokinetic and Pharmacodynamic Interactions Between Anti‐Asthma Drugs and Medicinal Plants: A Comprehensive Review

Phytotherapy Research, EarlyView.
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit, Aylin Bülbül, Betul Kocaadam‐Bozkurt, Osman Bozkurt, Duygu Ağagündüz, Raffaele Capasso   +5 more
wiley   +1 more source

Pregnancy in CTD‐interstitial lung disease: Current evidence, clinical challenges, and a proposed management algorithm

Rheumatology &Autoimmunity, EarlyView.
Summary of pregnancy management in CTD‐ILD across preconception, antenatal, and postpartum phases, emphasizing risk stratification and multidisciplinary care. 6MWT, 6‐min walk test; CTD‐ILD: connective tissue disease‐interstitial lung disease; DLCO, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; MDT, multidisciplinary ...
Khaled Aldhuaina, Ghaydaa Aldabie, Mohammad Abdulsalam, Ali Jawad   +3 more
wiley   +1 more source

Agreement between forced expiratory volume in the first second (FEV₁) and peak expiratory flow (PEF) in severe acute asthma. [PDF]

Lung India, 2022
Damaraju V, Nath A, Sehgal IS, Muthu V, Prasad KT, Dhooria S, Aggarwal AN, Agarwal R.   +7 more
europepmc   +1 more source

Clinical Outcomes and Acute Exacerbation Incidence in Combined Pulmonary Fibrosis and Emphysema

Respirology, EarlyView.
This multicentre prospective study of 1016 patients demonstrated that CPFE, defined as ≥ 5% emphysema on visual CT assessment, identified a high‐risk phenotype with significantly worse 5‐year survival compared to non‐CPFE IIP patients (51.4% vs. 63.1%) and COPD patients (51.4% vs. 84.0%) and higher acute exacerbation incidence, validating international
Kazuya Tsubouchi, Yasuaki Kotetsu, Tomotsugu Takano, Hiroaki Ogata, Fumiaki Kiyomi, Katsuyuki Ichiki, Shohei Takata, Yasuhiko Kitasato, Hiroshi Ishii, Kazuhiro Yatera, Kei Yamasaki, Masaki Okamoto, Makoto Yoshida, Masayuki Kawasaki, Masaki Fujita, Tomohiro Ogawa, Kazunori Tobino, Eiji Harada, Noriaki Nakagaki, Masashi Komori, Taishi Harada, Hiroshi Wataya, Yoichi Nakanishi, Isamu Okamoto   +23 more
wiley   +1 more source

Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry. [PDF]

ERJ Open Res, 2023
Hatziagorou E, Fieuws S, Orenti A, Naehrlich L, Krivec U, Mei-Zahav M, Jung A, De Boeck K, ECFSPR Collaborative Group, ECFSPR Collaborative Group .   +9 more
europepmc   +1 more source